Key result
Colchicine lacks reported clinical outcome data in CAD with elevated C-reactive protein.
Why the study?
Data evaluating the effectiveness of low-dose colchicine in real-world populations with coronary artery disease selected for elevated inflammatory burden remain limited.
Does colchicine improve clinical outcomes in patients with coronary artery disease and elevated C-reactive protein?
Observational
Does colchicine improve clinical outcomes in patients with coronary artery disease and elevated C-reactive protein?
Answers are grounded in this paper and cite their sources.
May support colchicine consideration in real-world CAD with elevated CRP; extends prior RCTs to inflammatory-risk populations.
Inflammation is a key driver of atherosclerotic coronary artery disease (CAD), and elevated C-reactive protein (CRP) identifies patients at heightened residual inflammatory risk despite contemporary lipid-lowering and antithrombotic therapy.1–3 Randomized trials, including COLCOT and LoDoCo2, have demonstrated cardiovascular benefit with low-dose colchicine in patients with chronic or recent CAD,4,5 but data evaluating its effectiveness in real-world populations selected for elevated inflammatory burden remain limited.
No takes yet. Share an insight, caveat, or question.
Dawoud et al. (2026) conducted an observational in Coronary artery disease and elevated C-reactive protein. Colchicine was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: